Our data suggest that Axitinib single treatment or in combination with PI3K inhibitors such as GDC‐0941 might prove a promising strategy to clinically target the most aggressive c‐myc‐amplified and SHH‐TP53‐mutated medulloblastoma subtypes. The gene discussed is TP53; the disease is medulloblastoma.